nodularis
Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis
Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody
Galderma’s IL-31 Blocker Nemluvio Gains FDA Approval for Prurigo Nodularis
Galderma, Nemluvio, IL-31 blocker, FDA approval, prurigo nodularis, therapeutic dermatology